Case Study: A Strategy to Eliminate Hemostatic Risk in Plasma-Derived Biotherapeutic Formulation

Resources

Case Study

Case Study: A Strategy to Eliminate Hemostatic Risk in Plasma-Derived Biotherapeutic Formulation

Human blood plasma is rich in proteins, including immunoglobulins (IgG), coagulationfactors (Factors II, VIII, IX, and X), alpha-1 antitrypsin, fibrin sealants, and albumin.These proteins boost the immune system and fight inflammation and infection, makingplasma-derived biotherapeutics useful in treating rare, chronic, and often geneticdiseases. Unfortunately, the current worldwide demand for intravenous IgG (IVIG)products exceeds current plasma […]

Case Study: A Strategy to Eliminate Hemostatic Risk in Plasma-Derived Biotherapeutic Formulation Read More »

Shopping Cart